Laboratory Corporation of America Holdings (NYSE:LH) – Investment analysts at KeyCorp issued their FY2017 earnings estimates for shares of Laboratory Corporation of America Holdings in a note issued to investors on Wednesday. KeyCorp analyst D. Hooker forecasts that the medical research company will post earnings per share of $9.54 for the year. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Laboratory Corporation of America Holdings’ Q4 2017 earnings at $2.36 EPS.

Several other analysts also recently commented on LH. Robert W. Baird reissued a “hold” rating and issued a $150.00 price objective on shares of Laboratory Corporation of America Holdings in a research note on Friday, October 27th. Craig Hallum reissued a “buy” rating and issued a $180.00 price objective (up from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Thursday, October 26th. Deutsche Bank AG increased their price objective on Laboratory Corporation of America Holdings from $170.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, ValuEngine downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $169.00.

TRADEMARK VIOLATION NOTICE: This piece was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://theolympiareport.com/2017/11/01/keycorp-weighs-in-on-laboratory-corporation-of-america-holdings-fy2017-earnings-lh.html.

Laboratory Corporation of America Holdings (NYSE LH) opened at 153.71 on Monday. The firm’s 50 day moving average price is $151.96 and its 200 day moving average price is $149.63. The firm has a market cap of $15.65 billion, a price-to-earnings ratio of 21.53 and a beta of 0.92. Laboratory Corporation of America Holdings has a 52-week low of $119.51 and a 52-week high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. The business’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.25 EPS.

Several institutional investors and hedge funds have recently modified their holdings of LH. Renaissance Technologies LLC increased its position in Laboratory Corporation of America Holdings by 171.8% in the first quarter. Renaissance Technologies LLC now owns 184,305 shares of the medical research company’s stock worth $26,442,000 after buying an additional 116,505 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in Laboratory Corporation of America Holdings by 0.6% in the first quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after buying an additional 15 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Laboratory Corporation of America Holdings in the first quarter worth $208,000. Barings LLC increased its position in Laboratory Corporation of America Holdings by 375.0% in the first quarter. Barings LLC now owns 12,729 shares of the medical research company’s stock worth $1,826,000 after buying an additional 10,049 shares during the last quarter. Finally, Tudor Investment Corp ET AL increased its position in Laboratory Corporation of America Holdings by 27.8% in the first quarter. Tudor Investment Corp ET AL now owns 2,300 shares of the medical research company’s stock worth $330,000 after buying an additional 500 shares during the last quarter. 93.39% of the stock is owned by institutional investors.

In related news, CEO David P. King sold 44,687 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the completion of the sale, the chief executive officer now directly owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider F Samuel Eberts III sold 31,500 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $155.22, for a total value of $4,889,430.00. Following the sale, the insider now directly owns 31,894 shares of the company’s stock, valued at $4,950,586.68. The disclosure for this sale can be found here. Insiders have sold 212,000 shares of company stock valued at $33,229,265 over the last ninety days. 0.90% of the stock is currently owned by company insiders.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.